Pulse Biosciences (PLSE)
NASDAQ:PLSE
Want to see PLSE full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.28Last Year’s EPS
-0.2Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress and clear operational momentum: landmark European feasibility results (strong efficacy and low SAE rate), initiation and acceleration of the U.S. pivotal IDE trial, regulatory milestones and expanded clinical programs (surgical clamp and Vybrance). These positive milestones were balanced against near‑term commercial immaturity (very small product revenue), rising R&D/clinical spend driving wider GAAP and non‑GAAP losses, and a material quarterly cash burn that reduced cash balances. Management has strengthened leadership, prioritized the high‑value catheter program and secured financing flexibility (shelf and ATM) to support execution. On balance, the clinical and operational advances meaningfully outweigh the financial and timing challenges reported.Company Guidance
Landmark European Feasibility Data — Strong Efficacy and Safety
European feasibility study (n=177) showed outstanding outcomes: 100% procedure success at 6 months (95/95 evaluable), 96% procedure success at 1 year (24-hour Holter evaluable), and a 90% Kaplan‑Meier estimated freedom from recurrent AF/atrial flutter/atrial tachycardia at 1 year. Safety profile: serious adverse event rate of 1.7% across 177 treated subjects.
U.S. IDE Pivotal Trial Initiated and Enrollment Accelerated
Commenced NANOPULSE‑AF IDE pivotal study in early April; first 7 patients treated in one day at St. Bernards (demonstrating short learning curve). Company tightened timeline and now expects enrollment completion in early Q4 2026 (accelerated from prior guidance of end-2026).
Procedural Efficiency and Single‑Shot Capability
nPulse catheter demonstrates single‑shot pulmonary vein ablation workflow (single 5‑second applications per target), with reported reductions in atrial dwell time, average number of applications, procedure time and fluoroscopy time — positioning the system as faster, reproducible and potentially capacity‑expanding for EP procedures.
Regulatory Pathway Momentum — CE and PMA Preparation
Plan to finalize CE submission in H2 2026 with potential CE Mark in mid‑2027 using European feasibility data; pivotal IDE design includes Bayesian analysis to shorten follow‑up and accelerate PMA module timing.
Surgical and Percutaneous Programs Advancing
Surgical clamp feasibility in Europe: >60 patients treated across 6 sites, average total ablation time ~41 seconds per patient and PVI success ~94% at ~3 months. Vybrance percutaneous system generated ~$400,000 in Q1 revenue; PRECISE‑BTN reached first 50 patients and expanded to 100. MD Anderson PTMC first‑in‑human enrollments completed in Q1.
Strategic Realignment and Strengthened Leadership
Company strategically prioritized the nPulse cardiac catheter program and increased R&D/clinical resourcing; Dr. David Kenigsberg transitioned to full‑time CMO and Liane Teplitsky hired as COO to support clinical, regulatory, quality and commercial execution.
Available Financing Flexibility
Cash and cash equivalents of $68.3M as of March 31, 2026, plus a $200M shelf registration and an ATM program with approximately $60M availability; Board approved participation by insiders in ATM and executives signaled intent to purchase shares, providing optionality to support operations.
PLSE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PLSE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 04, 2026 | $20.83 | $20.03 | -3.84% |
Feb 19, 2026 | $25.08 | $21.42 | -14.59% |
Nov 05, 2025 | $16.27 | $15.73 | -3.32% |
Aug 12, 2025 | $15.10 | $16.79 | +11.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pulse Biosciences (PLSE) report earnings?
Pulse Biosciences (PLSE) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Pulse Biosciences (PLSE) earnings time?
Pulse Biosciences (PLSE) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PLSE EPS forecast?
PLSE EPS forecast for the fiscal quarter 2026 (Q2) is -0.28.